BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28514203)

  • 21. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
    Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
    Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
    J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore.
    Cheng LJ; Soon SS; Tan TW; Tan CH; Lim TSK; Tay KJ; Loke WT; Ang B; Chiong E; Ng K
    BMC Health Serv Res; 2021 Sep; 21(1):909. PubMed ID: 34479565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
    Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
    J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
    BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience.
    Prando A; Kurhanewicz J; Borges AP; Oliveira EM; Figueiredo E
    Radiology; 2005 Sep; 236(3):903-10. PubMed ID: 16118169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy.
    Li CK; Tong BCY; You JHS
    Int J Infect Dis; 2016 Feb; 43():7-12. PubMed ID: 26686941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
    Pepe P; Pepe G; Pepe L; Garufi A; Priolo GD; Pennisi M
    Anticancer Res; 2018 Apr; 38(4):2395-2398. PubMed ID: 29599367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?
    Delongchamps NB; Portalez D; Bruguière E; Rouvière O; Malavaud B; Mozer P; Fiard G; Cornud F;
    J Urol; 2016 Oct; 196(4):1069-75. PubMed ID: 27079582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
    Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
    J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current beliefs and practice patterns among urologists regarding prostate magnetic resonance imaging and magnetic resonance-targeted biopsy.
    Muthigi A; Sidana A; George AK; Kongnyuy M; Maruf M; Valayil S; Wood BJ; Pinto PA
    Urol Oncol; 2017 Jan; 35(1):32.e1-32.e7. PubMed ID: 27743850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
    Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.
    Franiel T; Stephan C; Erbersdobler A; Dietz E; Maxeiner A; Hell N; Huppertz A; Miller K; Strecker R; Hamm B
    Radiology; 2011 Apr; 259(1):162-72. PubMed ID: 21233291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.
    Puech P; Rouvière O; Renard-Penna R; Villers A; Devos P; Colombel M; Bitker MO; Leroy X; Mège-Lechevallier F; Comperat E; Ouzzane A; Lemaitre L
    Radiology; 2013 Aug; 268(2):461-9. PubMed ID: 23579051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.
    Beyersdorff D; Taupitz M; Winkelmann B; Fischer T; Lenk S; Loening SA; Hamm B
    Radiology; 2002 Sep; 224(3):701-6. PubMed ID: 12202702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
    Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.